Jan 10, 2023 / 11:45PM GMT
Lut Ming Cheng - JPMorgan Chase & Co, Research Division - Research Analyst
Good afternoon, everyone. Thank you for joining us for another session at the 41st Annual JPMorgan Healthcare Conference. My name is Brian Cheng. I'm one of the senior biotech analysts here at the firm. Presenting next is Allogene. With us today, we have President and CEO of Allogene, David Chang.
I'll turn over the stage to David, and then the presentation will be followed by a Q&A session.
David D. Chang - Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director
Thank you, Brian, for hosting us, and thank you for those who are in the audience. So I will be making some forward-looking statements, which will be subject to the disclosures we have in the SEC filing.
So Allogene is really here to democratize the cell therapy and our mission is for the patients. And we have 6 foundational platforms from AlloCAR T, TurboCAR T, Cloak & Dagger, manufacturing as well as iPSC programs to fuel the innovation. Also, we distinguish ourselves by having
Allogene Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers